GlaxoSmithKline PLC (GSK): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

GlaxoSmithKline ( GSK) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.1%. By the end of trading, GlaxoSmithKline fell $1.02 (-1.8%) to $55.37 on heavy volume. Throughout the day, 3,783,457 shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 2,475,600 shares. The stock ranged in price between $54.67-$55.60 after having opened the day at $55.45 as compared to the previous trading day's close of $56.39. Other companies within the Health Care sector that declined today were: Synthetic Biologics ( SYN), down 30.9%, Auxilium Pharmaceuticals ( AUXL), down 17.7%, Prothena ( PRTA), down 15.8% and Usana Health ( USNA), down 15.7%.

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, such as vaccines, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $136.0 billion and is part of the drugs industry. The company has a P/E ratio of 18.8, above the S&P 500 P/E ratio of 17.7. Shares are up 4.9% year to date as of the close of trading on Tuesday. Currently there are 2 analysts that rate GlaxoSmithKline a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, compelling growth in net income, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.

On the positive front, AVANIR Pharmaceuticals ( AVNR), up 45.6%, IsoRay ( ISR), up 29.6%, Adamas Pharmaceuticals ( ADMS), up 15.3% and 22nd Century Group ( XXII), up 14.0% , were all gainers within the health care sector with Actavis ( ACT) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Swiss Franc Slides to Three-Year Low as U.S. Sanctions on Russian Oligarchs Bite

Swiss Franc Slides to Three-Year Low as U.S. Sanctions on Russian Oligarchs Bite

GE Beats Earnings Estimates and 4 Other Stories You Must Know Friday Morning

GE Beats Earnings Estimates and 4 Other Stories You Must Know Friday Morning

General Electric, Honeywell, Wells Fargo and Qualcomm - 5 Things You Must Know

General Electric, Honeywell, Wells Fargo and Qualcomm - 5 Things You Must Know

Oil Slips From Three-Year Peak After Trump Tweets Anger at OPEC

Oil Slips From Three-Year Peak After Trump Tweets Anger at OPEC

Global Stocks Hit by Asia Tech Weakness, Oil Price Rally; U.S. Futures Slip

Global Stocks Hit by Asia Tech Weakness, Oil Price Rally; U.S. Futures Slip